$10.85
▼ $-0.48
(-4.24%)
Vol 1.3M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$761.7M
ROE
-9.8%
Margin
-18.7%
D/E
0.07
Beta
1.87
52W
$6–$21
Wall Street Consensus
26 analysts · Apr 20266
Strong Buy
10
Buy
9
Hold
1
Sell
0
Strong Sell
61.5%
Buy Rating
Price Chart
Similar Stocks
About Arvinas, Inc. - Common Stock
ARVN Pharmaceuticals - це фармацевтична компанія, що спеціалізується на розробці та виробництві генеричних лікарських засобів та оригінальних препаратів. Компанія займає стабільну позицію на ринку завдяки широкому асортименту продукції та конкурентним цінам. Її ключова перевага - це здатність швидко виводити на ринок якісні генерики, а також інноваційні розробки.
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.60 | $-1.10 | $-0.50 |
| Sep 2025 | $-0.81 | $-0.48 | +$0.33 |
| Jun 2025 | $-1.02 | $-0.84 | +$0.18 |
| Mar 2025 | $-0.97 | $1.14 | +$2.11 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $59.2M | $188.8M | $22.4M | $41.9M | $9.5M |
| Net Income | — | -$45.1M | $82.9M | -$61.2M | -$35.1M | -$67.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -12.0% | -12.0% | -12.0% | -12.0% | -9.8% | -9.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -273.2% | -19.5% | -19.5% | -19.5% | -18.7% | -18.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 |
| Current Ratio | 5.64 | 5.64 | 5.64 | 5.64 | 5.70 | 5.70 |
Key Ratios
ROA (TTM)
-6.1%
P/S (TTM)
2.44
P/B
2.3
EPS (TTM)
$-0.80
CF/Share
$-5.17
Rev Growth 3Y
+78.0%
52W High
$21.00
52W Low
$5.90
$5.90
52-Week Range
$21.00
Financial Health
Free Cash Flow
-$30.6M
Net Debt
-$134.0M
Cash
$142.9M
Total Debt
$8.9M
As of Dec 31, 2025
How does ARVN compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ARVN valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
2.4
▼
51%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
2.4
▲
11%
above
peers
(2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ARVN profitability vs Pharmaceuticals peers
ROE
-9.8%
▲
82%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
-18.7%
▲
61%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-6.1%
▲
84%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
ARVN financial health vs Pharmaceuticals peers
D/E ratio
0.1
▼
95%
below
peers
(1.5)
vs Peers
vs Industry
Above avg
Current ratio
5.7
▲
70%
above
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
1.9
▲
99%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
ARVN fundamentals radar
ARVN
Peer median
Industry
ARVN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ARVN vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BERKOWITZ NOAH
Officer · Mar 18
6435 shs
MORRISON BRIGGS W. M.D.
Director · Mar 06
20000 shs
HOUSTON JOHN G
Director · Feb 27
35297 shs
BERKOWITZ NOAH
Officer · Feb 26
45000 shs
SAIK ANDREW
Chief Financial Officer · Feb 26
45000 shs
LOOMIS DAVID K
Officer · Feb 26
12420 shs
TEEL RANDY PH.D.
Chief Executive Officer · Feb 26
147791 shs
TEEL RANDY PH.D.
Chief Executive Officer · Feb 26
147179 shs
CACACE ANGELA M
Officer · Feb 26
45000 shs
LOOMIS DAVID K
Officer · Feb 23
1108 shs
Last 90 days
Top Holders
Top 5: 38.1%Blackrock Inc.
11.45%
$74.0M
Vanguard Group Inc
11.30%
$73.0M
Shaw D.E. & Co., Inc.
5.77%
$37.3M
Pfizer Inc
5.41%
$34.9M
TCG Crossover Management, L…
4.17%
$26.9M
As of Dec 31, 2025